ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1620718
This article is part of the Research TopicThe Association of Other Autoimmune Diseases in Patients with Thyroid Autoimmunity: Volume IIView all 25 articles
Correlation Between Different Levels of Thyroid Autoantibodies and Immune Checkpoint Inhibitor-Associated Thyroid Dysfunction
Provisionally accepted
- 1People's Hospital of Chengyang District, Qingdao, China
- 2Qingdao Chengyang District People’s Hospital, Qingdao, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: To investigate the correlation between thyroid immune-related adverse events (irAEs) and thyroid autoantibodies in cancer patients treated with immune checkpoint inhibitors (ICIs).: A retrospective analysis was conducted on 316 cancer patients (139 females, 177 males; median age 64.0 [56.0-71.0] years) treated at Qingdao Chengyang District People's Hospital from January 2018 to December 2023. Patients were divided into a euthyroid group (n = 158) and a thyroid irAEs group (n = 158) based on the occurrence of thyroid dysfunction post-ICI therapy. The researchers received at least one treatment with ICIs, and after the initial treatment, they underwent at least one or more tests for thyroid hormone levels, TPOAb, TRAb, and TgAb, with an interval of 4 weeks or more for each test. Thyroid hormone levels and autoantibodies (TPOAb, TRAb, TgAb) were measured. Clinical characteristics and baseline thyroid autoantibodies were evaluated for their association with thyroid irAEs.Results: Thyroid irAEs included subclinical thyrotoxicosis (19.94%, n = 63), clinical thyrotoxicosis (2.53%, n = 8), subclinical hypothyroidism (6.01%, n = 19), and clinical hypothyroidism (21.52%, n = 68). Baseline thyroid autoantibodies were positive in 28.48% (n = 45) of the irAEs group versus 5.70% (n = 9) in the euthyroid group (P < 0.001). Post-ICI treatment, the thyrotoxicosis group exhibited higher TRAb titers but lower TPOAb titers and TSH levels compared to the hypothyroidism group (P < 0.05).Logistic regression identified pre-treatment TRAb positivity (OR=6.927, 95% CI:1.817-32.724, P=0.002) and TPOAb positivity (OR = 7.128, 95% CI: 1.877-37.225, P = 0.001) as risk factors for thyroid irAEs.Patients with malignant tumors who had high levels of TPOAb and/or TRAb before treatment were more likely to develop thyroid immune-related adverse events (irAEs) after treatment. The importance of screening for baseline thyroid autoantibodies in predicting thyroid irAEs needs to be clearly understood, and close monitoring and notification to patients should be carried out, along with prior intervention.
Keywords: Neoplasms, Thyroid Gland, immune checkpoint inhibitors, immune-, Anti-thyroid peroxidase antibody, Thyrotropin receptor antibody, Anti-thyroglobulin antibody
Received: 30 Apr 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Jiao, Xu and Rao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaopang Rao, Qingdao Chengyang District People’s Hospital, Qingdao, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.